^
    Back
    Association details:
    Biomarker:RAD51B promoter methylation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    RAD51Bme as predictive biomarker for PD-1 blockade response in non-small cell lung cancer.

    Published date:
    05/13/2020
    Excerpt:
    RAD51Bme levels were analysed in samples of NSCLC obtained from patients not treated with anti-PD-1 blockade……and patients treated with anti-PD-1…RAD51Bme levels significantly associated with PD-L1 immunoexpression. Patients with clinical benefit from immunotherapy disclosed higher RAD51Bme levels (p = 0.04) and significantly higher median progression free survival (PFS) (p = 0.02)....We demonstrated that RAD51Bme levels might be combined with validated predictive biomarker PD-L1 immunostaining to select patients who will most likely experience clinical benefit from PD-1 blockade.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e15235